DIGITAL-MEDICINE-WHITEPAPER

August 26, 2016

How will digital technologies impact disease management and healthcare over the next decade?

Find out in the just-released whitepaper, "The Digital Medicine Crystal Ball: Unlocking the Future of Real-Time, Precise, Effective, Healthcare."

 

The last five years have seen an unprecedented eruption in technological and health advances.

These new technologies and products—many undergoing rigorous clinical validation—will have significant direct impacts on diagnosing, preventing, monitoring or treating a disease, condition or syndrome, which in turn will transform disease management and alter business models across industries.

This whitepaper describes the current and future influence of digital medicine on the health ecosystem and highlights how various stakeholders are working to deliver clinically impactful and economically viable solutions in a saturated yet still-emerging business environment.

 

Topics addressed in the whitepaper include:

 

  • How various stakeholders are working to deliver clinically impactful and economically viable solutions in a saturated yet still-emerging business environment

  • The new roles of traditional healthcare players

  • How the entrance of new technologies will affect partnership models and business strategies

  • The future of digital medicine’s regulatory environment

 

 

Author: Nicole Fisher

 

The report, produced by EBD Group in collaboration with Hogan Lovells, and authored by Forbes contributor, Nicole Fisher, features insights from Evidation Health, Hogan Lovells, J&J Innovation, NIH/PMI, Sanofi, StartUp Health, and key opinion leaders such as John Nosta and Unity Stoakes.

 

 

 

 


Meet innovative companies in this emerging field as well as potential collaborators featured in this whitepaper at Digital Medicine Connect, a one-day partnering event taking place during BioPharm America™ on September 15, 2016. Learn more.

Digital Medicine Connect at BioPharm America

 

 

 

Share your email address with EBD Group to open the whitepaper. Unsubscribe to our news at any time. Learn More: EBD Group Terms of Use Privacy Policy

Previous Article
How are regulatory changes affecting early stage R&D in China?
How are regulatory changes affecting early stage R&D in China?

Darren Ji discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes f...

Next Article
Dimerix CEO explains company’s different drug combo R&D strategy
Dimerix CEO explains company’s different drug combo R&D strategy

Kathy Harrison, CEO of Australian biotech Dimerix, talks about the company's unusual business model, Dimeri...